Grilinctus-BM Tablet is a combination pharmaceutical formulation containing Terbutaline sulfate 2.5 mg and Bromhexine hydrochloride 8 mg, indicated for the management of respiratory conditions characterized by bronchospasm and excessive mucus secretion. Terbutaline, a selective beta-2 adrenergic receptor agonist, acts as a bronchodilator by relaxing bronchial smooth muscle, thereby facilitating improved airflow and alleviating symptoms of bronchospasm associated with asthma, chronic bronchitis, and other obstructive airway diseases. Bromhexine serves as a mucolytic agent, enhancing the clearance of mucus by breaking down mucopolysaccharide fibers, reducing sputum viscosity, and promoting expectoration. The synergistic action of these two active ingredients aids in relieving cough and improving respiratory function. Grilinctus-BM is typically administered orally, with dosage tailored according to patient age, severity of symptoms, and clinical response. It is contraindicated in patients with hypersensitivity to any component, and caution is advised in individuals with cardiovascular disorders, hyperthyroidism, or diabetes mellitus due to Terbutaline’s systemic effects. Common adverse reactions may include tremors, palpitations, gastrointestinal discomfort, and allergic reactions. Grilinctus-BM should be used under medical supervision, with adherence to prescribed dosage and monitoring for potential side effects to ensure optimal therapeutic outcomes.